Latest Global Markets News

Page 3 of 67
Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.
Ada Torres
Ada Torres
26 Aug 2026
Advanced Braking Technology Ltd (ASX: ABV) posted a 22.7% revenue increase to $23.48 million and a 16.6% rise in net profit after tax to $2.075 million for FY26, driven by international expansion and advances in autonomous braking technology.
Victor Sage
Victor Sage
26 Aug 2026
Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.
Ada Torres
Ada Torres
25 Aug 2026
Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.
Sophie Babbage
Sophie Babbage
25 Aug 2026
Woodside Energy delivered a strong first half in 2026, with revenue up 13% to $7.45 billion, net profit after tax reaching $1.67 billion, and key LNG and oil projects advancing on schedule. The company declared a fully franked interim dividend of 57 US cents per share amid ongoing global market volatility.
Maxwell Dee
Maxwell Dee
25 Aug 2026
Advanced Engineered Materials (ASX:AEM) reported an 85% jump in high purity alumina sales in 1H 2026, with a customer pipeline now valued at US$190 million amid tightening global supply and rising semiconductor industry demand.
Maxwell Dee
Maxwell Dee
24 Aug 2026
Lightning Minerals has reinforced the Warby Tungsten Project's potential with Phase 2 rock chip assays showing five of six samples above 1% tungsten, peaking at 5.46%, and revealing polymetallic mineralisation including gold and tin. The company awaits further soil and drainage assay results to shape Phase 3 exploration.
Maxwell Dee
Maxwell Dee
24 Aug 2026
Cadence Opportunities Fund delivered a standout FY26 with profit after tax soaring 279% to $5.66 million and a 30.3% fund return, prompting a fully franked final dividend and a special payout.
Claire Turing
Claire Turing
21 Aug 2026
Cadence Capital Limited delivered a stellar 434% jump in profit after tax to $33.4 million for FY26, driven by a 313% revenue surge. The company declared a 3.0 cent fully franked final dividend plus a 1.0 cent special dividend, underpinning a strong yield amid active portfolio repositioning.
Claire Turing
Claire Turing
21 Aug 2026
Inghams Group delivered modest revenue growth in FY26 but saw net profit collapse amid cost pressures and tax disputes. Executive short-term incentives were forfeited, while the company declared a fully franked dividend and outlined a cautious FY27 outlook.
Victor Sage
Victor Sage
21 Aug 2026
Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.
Ada Torres
Ada Torres
20 Aug 2026
AnteoTech has formalised a strategic alliance with South Korea’s Xerabrid to co-develop and commercialise a breakthrough battery separator combining their proprietary technologies, targeting high-performance applications in eVTOL, EVs, and consumer electronics.
Victor Sage
Victor Sage
20 Aug 2026

Browse the archive

Full archive